Arcturus Therapeutics Holdings Inc. (ARCT) News
Filter ARCT News Items
ARCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARCT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ARCT News From Around the Web
Below are the latest news stories about ARCTURUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
Arcturus Therapeutics launches Phase I Avian Influenza trials in USThe announcement follows just days after the US Centres for Disease Control confirmed its first death from the zoonotic disease. |
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine TrialSAN DIEGO, January 10, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the initiation of the Company’s Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H |
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) DeficiencySAN DIEGO, January 06, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company’s Phase 2 multiple ascending dose studies. |
High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two OthersOver the last 7 days, the United States market has experienced a 2.2% drop, yet it is up 24% over the past year with earnings forecast to grow by 15% annually. In this context of fluctuating yet promising growth, identifying high-growth tech stocks such as Arcturus Therapeutics Holdings requires an understanding of their potential to capitalize on technological advancements and market opportunities amidst these dynamic conditions. |
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, December 16, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time. |
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short SellersWe recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most well-known […] |
Arcturus Therapeutics to Attend Upcoming Investor ConferencesSAN DIEGO, November 26, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: |
Arcturus Therapeutics to Present at Jefferies London Healthcare ConferenceSAN DIEGO, November 19, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. |
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.TOKYO, November 14, 2024--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS"). |